Research output per year
Research output per year
- 1 - 50 out of 161 results
Search results
-
2025
Adding New Agents to Treatment Protocols for Patients with CKD
Tuttle, K., Jan 1 2025Research output: Other contribution
-
GLP 1 Receptor Agonism FLOWS into the Mainstream for Chronic Kidney Disease
Tuttle, K., Jan 1 2025Research output: Other contribution
-
Interview with Katherine Tuttle and Jonathan Barratt
Tuttle, K., Mar 1 2025Research output: Other contribution
-
Outcomes of Critical Limb Threatening Ischemia Revascularization in Patients with Chronic Kidney Disease in the BEST - CLI Trial
Tuttle, K., Jan 1 2025Research output: Other contribution
-
-
“Celebrating Dr. Steven Packer with those who know him well”
Tuttle, K., Mar 1 2025Research output: Other contribution
-
“Goal for Saving Kidneys, Hearts and Lives”
Tuttle, K., Mar 1 2025Research output: Other contribution
-
“Most-cited paper – Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.”
Tuttle, K., Mar 1 2025Research output: Other contribution
-
2024
379. SGLT Inhibitors: The Biology of SGLT Inhibition with Dr. Katherine Tuttle
Tuttle, K., Aug 1 2024Research output: Other contribution
-
Clinical and Mechanistic Effects of GLP-1 Receptor Agonists in CKD
Tuttle, K., Dec 1 2024Research output: Other contribution
-
GLP-1 Receptor Agonists for CKD in Diabetes and Beyond…
Tuttle, K., Jan 1 2024Research output: Other contribution
-
Helio “Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor”
Tuttle, K., Jan 1 2024Research output: Other contribution
-
-
"National Academies Workshop – Preparing the Future Workforce in Drug andResearch Development"
Tuttle, K., Apr 1 2024Research output: Other contribution
-
National Geographic Interview feature article
Tuttle, K., Apr 1 2024Research output: Other contribution
-
Plenary - “Kidney Health and CKD Prevention Herald a Sea Change in Nephrology”
Tuttle, K., Jun 1 2024Research output: Other contribution
-
-
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality Outcomes
Tuttle, K., Dec 1 2024Research output: Other contribution
-
Transforming CKD Care from Evidence Generation to Implementation
Tuttle, K., Dec 1 2024Research output: Other contribution
-
Treatment of Chronic Kidney Disease and Heart Failure Circa 2024
Tuttle, K., Dec 1 2024Research output: Other contribution
-
-
-
“Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status of Risk in the FLOW Trial."
Tuttle, K., Nov 1 2024Research output: Other contribution
-
“Benefits of semaglutide on chronic kidney disease outcomes by cardiovascular status or risk in the FLOW trial."
Tuttle, K., Nov 1 2024Research output: Other contribution
-
-
“Cases in Diabetes, Kidney, and Cardio-Renal-Metabolic Disease”
Tuttle, K., Apr 1 2024Research output: Other contribution
-
“Diabetic Nephropathy 2024: Comprehensive Care for People with Diabetes Mellitus and Advanced Chronic Kidney Disease."
Tuttle, K., Nov 1 2024Research output: Other contribution
-
“DM and CKD Treatments: Which Treatment Should I Use for Different Populations?”
Tuttle, K., Apr 1 2024Research output: Other contribution
-
“Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW)”
Tuttle, K., Oct 1 2024Research output: Other contribution
-
“FLOW: A new treatment paradigm for people with T2D and chronic kidney disease”
Tuttle, K., Jun 1 2024Research output: Other contribution
-
“FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk.”
Tuttle, K., Nov 1 2024Research output: Other contribution
-
“FLOW: Semaglutide scores big in diabetic patients with CKD”
Tuttle, K., May 1 2024Research output: Other contribution
-
“FLOW Result: Summary and Clinical Implication
Tuttle, K., Jun 1 2024Research output: Other contribution
-
-
“GLP-1 Receptor Agonists for CKD in Diabetics and Beyond”
Tuttle, K., Feb 1 2024Research output: Other contribution
-
“Glycemic Management in Persons with Diabetes and CKD”
Tuttle, K., Apr 1 2024Research output: Other contribution
-
“Going with the FLOW: Understanding the renal effects of GLP-1RA Therapy”
Tuttle, K., Nov 1 2024Research output: Other contribution
-
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”
Tuttle, K., Dec 1 2024Research output: Other contribution
-
“How Will the Incretin Data “FLOW” into Practice?”
Tuttle, K., Oct 1 2024Research output: Other contribution
-
“ Key considerations for tailoring treatment approaches for diabetic patients with chronic kidney disease"
Tuttle, K., May 1 2024Research output: Other contribution
-
“Kidney Compass Podcast with Drs. Neuen/Wadhwani & Tuttle
Tuttle, K., Oct 1 2024Research output: Other contribution
-
“Kidney Health for All: Advancing equitable access to care and optimal medication practice”
Tuttle, K., Feb 1 2024Research output: Other contribution
-
-
-
-
“Miracle weight-loss drugs could halt kidney disease too”
Tuttle, K., Feb 1 2024Research output: Other contribution
-
“Navigating the Sea Change of CKD Treatment in Diabetes”
Tuttle, K., Nov 1 2024Research output: Other contribution
-
-
“New study shows Ozempic lowers kidney disease”
Tuttle, K., May 1 2024Research output: Other contribution
-